导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -0.63% | 2367/4773 |
| 近一周 | -2.84% | 3246/5462 |
| 近一月 | -6.99% | 3695/5421 |
| 近一季 | -13.20% | 3956/5209 |
| 近半年 | -5.59% | 2902/4920 |
| 近一年 | 3.28% | 1954/4366 |
| 近两年 | 66.23% | 1049/2954 |
| 近三年 | 34.37% | 888/2253 |
| 成立以来 | 30.98% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.43% 1802/4961 |
19.93% 1267/5312 |
- - |
- - |
| 2025 | 29.89% 1366/4813 |
0.85% 1752/3635 |
0.46% 2641/4076 |
28.08% 1285/4524 |
0.11% 2210/4813 |
| 2024 | 10.62% 1396/3463 |
-1.35% 1215/2808 |
-4.55% 1523/3014 |
18.33% 1022/3129 |
-0.72% 1502/3463 |
| 2023 | -12.20% 1456/2656 |
6.02% 734/2280 |
-5.00% 1337/2385 |
-7.68% 1609/2515 |
-5.58% 1405/2655 |
| 2022 | -24.15% 1193/2207 |
-17.70% 1245/1919 |
6.79% 604/2016 |
-15.42% 1285/2113 |
2.04% 1057/2208 |
| 2021 | 5.09% 556/1822 |
-4.27% 855/1255 |
10.69% 442/1330 |
-4.45% 709/1466 |
3.80% 389/1822 |
| 2020 | 40.64% 308/1250 |
-4.17% 342/1028 |
20.18% 280/1067 |
9.14% 669/1164 |
11.89% 511/1184 |
| 2019 | 43.09% 196/1092 |
34.67% 107/754 |
-6.29% 499/804 |
3.23% 263/850 |
9.84% 185/918 |
| 2018 | -32.17% 521/834 |
- - |
- - |
- - |
-13.00% 502/691 |
| 2017 | 9.27% 307/714 |
- - |
- - |
- - |
- - |
| 2016 | -17.77% 400/605 |
- - |
- - |
- - |
- - |
| 2015 | 15.13% 142/575 |
- - |
- - |
- - |
- - |
| 2014 | 35.49% 145/237 |
- - |
- - |
- - |
- - |
| 2013 | -8.73% 138/186 |
- - |
- - |
- - |
- - |
| 2012 | 2.62% 93/140 |
- - |
- - |
- - |
- - |
| 2011 | -27.05% 81/102 |
- - |
- - |
- - |
- - |
| 2010 | -5.79% 15/58 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 南方深证成份ETF联接A VS. 长安沪深300非周期A(740101) |